MX2018002707A - Derivados de tetrahidrofurano antivirales. - Google Patents

Derivados de tetrahidrofurano antivirales.

Info

Publication number
MX2018002707A
MX2018002707A MX2018002707A MX2018002707A MX2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A
Authority
MX
Mexico
Prior art keywords
compounds
viral
tetrahydrofurane
derivatives
tetrahydrofurane derivatives
Prior art date
Application number
MX2018002707A
Other languages
English (en)
Spanish (es)
Inventor
A Degoey David
C Krueger Allan
T Randolph John
Wagner Rolf
R Heyman Howard
Voight Eric
CHAU Jaclyn
Ju J Chen Hui-
Hartung John
Ide Nathan
Kalthod Vikram
Yin KU Yi-
Li Tongmei
T Halvorsen Geoff
C Marvin Christopher
S Brown Brian
R Martinez Steven
Shrestha Anurupa
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018002707A publication Critical patent/MX2018002707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2018002707A 2015-09-02 2016-09-01 Derivados de tetrahidrofurano antivirales. MX2018002707A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562213378P 2015-09-02 2015-09-02
US201562242136P 2015-10-15 2015-10-15
US201562253426P 2015-11-10 2015-11-10
US201662294449P 2016-02-12 2016-02-12
US201662296801P 2016-02-18 2016-02-18
US201662321538P 2016-04-12 2016-04-12
US201662327087P 2016-04-25 2016-04-25
US201662351038P 2016-06-16 2016-06-16
US201662363640P 2016-07-18 2016-07-18
US201662375029P 2016-08-15 2016-08-15
PCT/US2016/049873 WO2017040766A1 (en) 2015-09-02 2016-09-01 Anti-viral tetrahydrofurane derivatives

Publications (1)

Publication Number Publication Date
MX2018002707A true MX2018002707A (es) 2018-08-01

Family

ID=56926317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002707A MX2018002707A (es) 2015-09-02 2016-09-01 Derivados de tetrahidrofurano antivirales.

Country Status (7)

Country Link
US (2) US9676797B2 (enExample)
EP (1) EP3344642A1 (enExample)
JP (1) JP6743135B2 (enExample)
CN (1) CN108350016B (enExample)
CA (1) CA2997170A1 (enExample)
MX (1) MX2018002707A (enExample)
WO (1) WO2017040766A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
US20190358214A1 (en) * 2016-11-17 2019-11-28 Abbvie Inc. Compositions and Methods for Treating HCV Infection
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CA3088287A1 (en) * 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6060542A (en) 1997-05-16 2000-05-09 Shell Oil Company Bitumen compositions and a process for their preparation
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
TR200402565T4 (tr) 2000-05-26 2004-12-21 Idenix (Cayman) Limited Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
DE60121986T2 (de) * 2000-10-02 2007-07-26 Emory University Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
CN101415719A (zh) * 2003-03-20 2009-04-22 微生物化学及药品有限公司 生产2’-脱氧-β-L-核苷的方法
FI2604620T4 (fi) 2003-05-30 2024-09-11 Gilead Pharmasset Llc Modifioituja fluorinoituja nukleosidianalogeja
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
RS52854B (sr) 2009-06-11 2013-12-31 Abbvie Bahamas Limited Inhibitori hepatitis c virusa
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
PT3290428T (pt) * 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
JP6043338B2 (ja) * 2011-04-13 2016-12-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体
JP2014515023A (ja) * 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
PL2794629T3 (pl) * 2011-12-20 2018-02-28 Riboscience Llc 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv
KR101687084B1 (ko) * 2011-12-20 2016-12-15 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
CN104640444B (zh) * 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
CN102751200B (zh) 2012-06-29 2015-06-10 京东方科技集团股份有限公司 薄膜晶体管、阵列基板及其制造方法
US20140065101A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-Branched Nucleosides for Treatment of Viral Infections
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR102532198B1 (ko) 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
BR112015025716A2 (pt) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
EP3057976A1 (en) * 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
WO2015077360A2 (en) * 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CA2946867C (en) 2014-04-24 2023-03-07 Cocrystal Pharma, Inc. 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US20170334941A1 (en) 2014-10-31 2017-11-23 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体

Also Published As

Publication number Publication date
CN108350016B (zh) 2021-07-27
US9676797B2 (en) 2017-06-13
JP6743135B2 (ja) 2020-08-19
US20170057981A1 (en) 2017-03-02
US20180022763A1 (en) 2018-01-25
JP2018529671A (ja) 2018-10-11
WO2017040766A1 (en) 2017-03-09
CN108350016A (zh) 2018-07-31
US10053474B2 (en) 2018-08-21
EP3344642A1 (en) 2018-07-11
CA2997170A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12020550531A1 (en) Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv)
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
PH12013500708B1 (en) Anti-viral compounds
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12013502033A1 (en) Pyrimidine derivatives for the treatment of viral infections
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
MX2015011193A (es) Compuestos antivirales.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
HK1251010A1 (zh) 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
GB2544439A (en) Antiviral composition
WO2017161133A8 (en) N-hydroxyisoquinolinedione inhibitors of hbv replication
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
MX2015010892A (es) Compuestos antivirales.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
MX2015011125A (es) Compuestos antivirales.
MY164064A (en) Anti-viral compounds